Ei­sai chief Ivan Che­ung 'not wor­ried at al­l' about Leqem­bi's full ap­proval

Days af­ter Ei­sai and Bio­gen se­cured an ac­cel­er­at­ed ap­proval for their Alzheimer’s drug Leqem­bi, Ei­sai US chair­man and CEO Ivan Che­ung is con­fi­dent about the path to a full ap­proval.

“Whether there’s an ad­vi­so­ry com­mit­tee or not, we are not wor­ried at all,” Che­ung told End­points News dur­ing a fire­side chat Wednes­day at this year’s JP Mor­gan Health­care Con­fer­ence.

He said it’s too soon to know whether the FDA will hold an ad­vi­so­ry com­mit­tee meet­ing ahead of the de­ci­sion, but added that “this ro­bust pack­age we be­lieve quite clear­ly of­fers mean­ing­ful ben­e­fits to pa­tients and care­givers and so­ci­ety.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER